← Leaderboards
Tai L Guo
Virginia Commonwealth University
$1,070,855
Attributed
$1,302,854
Total exposure
4
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $239K · FY2005–19$250K$187.5K$125K$62.5K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$1,302,854 · 4
By mechanism
R21$838,855 · 2
R41$463,999 · 2
Top collaborators
- Yingjia Chen1 shared
- Sheng-Cheng Wu1 shared
Most similar at Virginia Commonwealth University
Same institution · by research overlap
- Jennifer T Wolstenholme$3,427,439
Others in their field
Top investigators on “Design”
- Lawrence Corey · Fred Hutchinson Cancer Center$736,542,541
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$460,267,569
- Jeffrey P Krischer · University Of South Florida$427,700,530
- David R. Weir · University Of Michigan At Ann Arbor$385,316,144
Research focus
DesignGenisteinDna MethylationOral AdministrationProductionEnvironmental ExposureLaboratory MouseInvestigationOrganInbred Nod MiceInterleukin 4Intervention StudiesAutoimmunityLeadIncidenceBaseAutoimmune DiseasesBiological MarkersAdultDoseGlucoseHelper T LymphocyteInterleukin 13Insulin-Dependent Diabetes Mellitus
Grant awards (7)
Prevention of type 1 diabetes using early glycation products$239,000
R41 · FY2019 · DK
Engineering probiotics to biosynthesize natural substances for microbiome-brain research$224,999
R41 · FY2017 · AT
Exacerbation of type 1 diabetes in mice by bisphenol A and genistein$225,000
R21 · FY2015 · ES · contact PI
Exacerbation of type 1 diabetes in mice by bisphenol A and genistein$186,355
R21 · FY2014 · ES · contact PI
Genistein Exacerbation of Asthma in Mice$142,500
R21 · FY2005 · ES
Genistein Exacerbation of Asthma in Mice$142,500
R21 · FY2004 · ES
Genistein Exacerbation of Asthma in Mice$142,500
R21 · FY2003 · ES